Earli, which raised $105M in two rounds, is developing 'Cancer-Activated Promoters' that are set off by cancer-specific transcription factors and turn tumor cells into therapeutic payload factories

BiotechTV - News - Earli, which raised $105M in two rounds, is developing 'Cancer-Activated Promoters' that are set off by cancer-specific transcription factors and turn tumor cells into therapeutic payload factories